Getinge Accelerates Growth and Productivity to Reach New Financial Targets

Getinge Accelerates Growth and Productivity to Reach New Financial Targets
share Share

Getinge’s new financial targets for 2022-2025, an annual organic net sales growth of 4-6% and adjusted EPS growth of above 10% on average throughout the period, is well in line with our strategy and ambitions”, says Mattias Perjos, President & CEO at Getinge. “Our continued organic growth and improved margins will be fueled with bolt on M&A’s for which we have significant capacity.”


The base scenario for reaching the adjusted EPS growth target will be a gradual improvement of EBITA margin to 21% or more by the end of the period. In addition to this, further net sales growth and operating profit will be added from selective acquisitions, for which Getinge has significant capacity.


“Looking back at what we have accomplished since the Capital Markets Day in 2018, we have delivered growth of above 4% CAGR and an EBITA margin improvement of approximately 8 percentage points to 19.0%”, continues Mattias Perjos. “We will continue to improve productivity, while we also gravitate our business growth towards product areas and markets with high growth and margins – both organically and through M&As.”


Getinge has for the past years implemented its strategy which has lead to a significant increase in both customer and employee satisfaction. In addition, the company’s product offering has been strengthened within growth areas and the company has set out an ambitions sustainabililty agenda for the coming years. In October 2021, the company announced the finalization of its remediation measures which enables Getinge to focus on more forward looking activities.


“Our solutions are needed more than ever to tackle global health care challenges”, says Mattias Perjos. “We will continue to deliver value to our customers through our products, solutions and selective M&A’s with a good strategic fit.”


Getinge’s Capital Markets Day will start at 3.00 pm (CET) and to participate at the event, please register via this link. More information will also be provided via Getinge’s websiteDuring the event, the company will present the next steps to strengthen the effects of the continuous improvement work and to take advantage of organic and acquisition related opportunities with increased intensity – given Getinge’s unique technological competence, global presence and solid financial position.


This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1.20 pm CET on November 22, 2021.

«« Surviving Sepsis Campaign Guidelines and Individualised Care


Efficacy, Appropriateness of Antibiotic Use in the ICU »»

Published on : Mon, 22 Nov 2021



Related Articles

Getinge has been present in Vietnam for more than 40 years through distributors. Now, the global medtech company expands the... Read more

Getinge is announcing a global medical device recall related to specific  Sevoflurane vaporizers for Flow Family Anesthesia... Read more

Getinge has been awarded a new 3-year Anesthesia contract from Premier Inc, a healthcare improvement company in the United States.... Read more

growth, Getinge, Mattias Perjos, Financial targets Getinge Accelerates Growth and Productivity to Reach New Financial Targets

No comment


Please login to leave a comment...

Highlighted Products